Όλο το DSpace

Εμφάνιση απλής εγγραφής

Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition

dc.creatorSkendros P., Papagoras C., Lefaki I., Giatromanolaki A., Kotsianidis I., Speletas M., Bocly V., Theodorou I., Dalla V., Ritis K.en
dc.date.accessioned2023-01-31T09:57:33Z
dc.date.available2023-01-31T09:57:33Z
dc.date.issued2017
dc.identifier10.1111/bjd.14685
dc.identifier.issn00070963
dc.identifier.urihttp://hdl.handle.net/11615/79086
dc.description.abstractGeneralized pustular psoriasis (GPP) is a severe type of psoriasis accompanied by systemic and often life-threatening manifestations. The efficacy of the interleukin (IL)-1 antagonist anakinra in cases of GPP underscores the role of IL-1 in disease pathogenesis. We present a case of a middle-aged man who developed an abrupt and severe form of GPP with severe eosinophilia and cholestatic hepatitis. The patient received salvage treatment with a combination of glucocorticoids, hydroxyurea and imatinib, while administration of the IL-1 inhibitor anakinra resulted in remission of hepatitis and a significant skin improvement. However, due to persistent hypersensitivity skin reactions, anakinra was withdrawn and replaced with the anti-IL-1β antagonist canakinumab. As a result of canakinumab, the patient's skin completely cleared, while no systemic manifestations recurred. After 1 year of continuous canakinumab therapy, the patient remained virtually free of symptoms, while the drug was well tolerated. © 2016 British Association of Dermatologistsen
dc.language.isoenen
dc.sourceBritish Journal of Dermatologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84997113282&doi=10.1111%2fbjd.14685&partnerID=40&md5=9d1d4e99a2cf13479ebd6b3fc7a4feea
dc.subjectanakinraen
dc.subjectantibiotic agenten
dc.subjectcanakinumaben
dc.subjectfresh frozen plasmaen
dc.subjectglucocorticoiden
dc.subjecthydroxyureaen
dc.subjectimatiniben
dc.subjectinterleukin 1betaen
dc.subjectmethylprednisoloneen
dc.subjectprednisoloneen
dc.subjectcanakinumaben
dc.subjectdermatological agenten
dc.subjectinterleukin 1 receptor blocking agenten
dc.subjectinterleukin 1betaen
dc.subjectmonoclonal antibodyen
dc.subjectadulten
dc.subjectArticleen
dc.subjectcase reporten
dc.subjectCaucasianen
dc.subjectcholestasisen
dc.subjectcholestatic hepatitisen
dc.subjectdiabetes mellitusen
dc.subjectdrug dose reductionen
dc.subjectdrug efficacyen
dc.subjectdrug substitutionen
dc.subjectdrug tolerabilityen
dc.subjectdrug withdrawalen
dc.subjectechographyen
dc.subjecteosinophiliaen
dc.subjecterythemaen
dc.subjecterythrodermaen
dc.subjectfeveren
dc.subjecthepatitis Ben
dc.subjecthumanen
dc.subjecthypereosinophilic syndromeen
dc.subjecthypersensitivityen
dc.subjecthypoalbuminemiaen
dc.subjectjaundiceen
dc.subjectlethargyen
dc.subjectleukocytosisen
dc.subjectlow drug doseen
dc.subjectlymphadenopathyen
dc.subjectmaleen
dc.subjectmiddle ageden
dc.subjectnuclear magnetic resonance imagingen
dc.subjectpriority journalen
dc.subjectpruritusen
dc.subjectpsoriasis vulgarisen
dc.subjectpustular psoriasisen
dc.subjectpustuleen
dc.subjectrashen
dc.subjectremissionen
dc.subjectsalvage therapyen
dc.subjectskin manifestationen
dc.subjectStaphylococcus infectionen
dc.subjecttopical treatmenten
dc.subjecttreatment responseen
dc.subjecturticariaen
dc.subjectantagonists and inhibitorsen
dc.subjectchemically induceden
dc.subjectpsoriasisen
dc.subjecttreatment outcomeen
dc.subjectAntibodies, Monoclonalen
dc.subjectDermatologic Agentsen
dc.subjectHumansen
dc.subjectInterleukin 1 Receptor Antagonist Proteinen
dc.subjectInterleukin-1betaen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPsoriasisen
dc.subjectTreatment Outcomeen
dc.subjectBlackwell Publishing Ltden
dc.titleSuccessful response in a case of severe pustular psoriasis after interleukin-1β inhibitionen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής